# Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

> **NCT00002663** · PHASE1,PHASE2 · COMPLETED · sponsor: **Atara Biotherapeutics** · enrollment: 58 (actual)

## Conditions studied

- EBV-induced Lymphomas
- EBV-associated Malignancies
- Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma

## Interventions

- **BIOLOGICAL:** Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)

## Key facts

- **NCT ID:** NCT00002663
- **Lead sponsor:** Atara Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-03
- **Primary completion:** 2019-07
- **Final completion:** 2019-07
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2023-02-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002663, "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*